Training nurses like athletes

Chandler Browning always dreamed of being part of The University of Texas at Arlington's nationally recognized nursing program and pursuing her goal of becoming a certified registered nurse anesthetist. Now in her first semester as a nursing student, she is experiencing firsthand UTA's latest innovation in nursing education: treating nurses as "clinical athletes."

Trial supports MRI surveillance over preventive brain radiation in small-cell lung cancer

Results from the international phase 3 SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC). The findings support MRI surveillance alone as the standard of care for patients with SCLC, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy. The findings were presented today at the IASLC 2026 World Conference on Lung Cancer (WCLC).

Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer

The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Simple perception test can accurately predict success of laser surgery for age-related vision loss

Laser blended vision is a treatment for presbyopia, the natural deterioration of our ability to see things close up that develops in people 40 and older. This type of laser surgery aims to correct one eye for seeing clearly in the distance and the other for near vision. It relies on the brain's ability to coordinate both eyes for clear vision at all ranges, which most, but not all, people can do.

Shedding new light on DNA repair in early human embryos, with implications for gene editing

Treating inherited diseases is one of the greatest challenges in modern medicine. In the future, targeted gene corrections at the earliest stages of embryonic development could help prevent certain inherited diseases from developing and being passed on to future generations. However, the safety of such approaches depends on how human embryos repair the DNA damage caused during gene editing and on the limitations of available technologies. These questions are addressed in a study published in the journal Nature, led by first author Štěpán Jeřábek, who is affiliated with both Columbia University and IOCB Prague. The research also involved two other IOCB Prague scientists, Iva Pichová and Michal Doležal.